Case report: A variant of the \textit{FIG4} gene with rapidly progressive amyotrophic lateral sclerosis

Mubalake Yilihamu\textsuperscript{1,2,3}, Xiaolu Liu\textsuperscript{1,2,3}, Xiaoxuan Liu\textsuperscript{1,2,3}, Yong Chen\textsuperscript{1,2,3} and Dongsheng Fan\textsuperscript{1,2,3,*}

\textsuperscript{1}Department of Neurology, Peking University Third Hospital, Beijing, China, \textsuperscript{2}Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China, \textsuperscript{3}Key Laboratory for Neuroscience, National Health Commission/Ministry of Education, Peking University, Beijing, China

Heterozygous autosomal-dominant \textit{FIG4} mutations are associated with amyotrophic lateral sclerosis (ALS). Here, we describe a variant of the \textit{FIG4} gene (c.350dupC, p.Asp118GlyfsTer9) in a patient with rapidly progressive ALS that has not previously been reported in ALS or primary lateral sclerosis (PLS) patients before. Our study provides further information on the genotypes and phenotypes of patients with \textit{FIG4} mutations.

**KEYWORDS**
amyotrophic lateral sclerosis, FIG4, mutation, genetics, case report

**Introduction**

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that selectively impairs the motor cortex, the motor neurons of the brainstem and the spinal cord (1). Nearly 10% of ALS cases are classified as familial ALS (FALS), whereas the remaining 90% of cases are considered sporadic ALS (SALS) (2). Factor-induced gene 4 (\textit{FIG4}), also known as \textit{SAC3}, encodes a phosphatase that regulates phosphatidylinositol 3,5-bisphosphate, a molecule critical for intracellular vesicle trafficking along the endosomal-lysosomal pathway (3). Mutations of \textit{FIG4} lead to the development of Charcot-Marie-Tooth disease type 4J (CMT-4J), ALS and primary lateral sclerosis (PLS) (4). Until now, only a few clinical reports of patients with ALS with \textit{FIG4} mutations exist (5). We report the case of a 55-year-old Chinese patient with rapidly progressing ALS possibly associated with a heterozygous \textit{FIG4} mutation (c.350dupC, p.Asp118GlyfsTer9). To date, this mutation has not been described in ALS patients.

**Case report**

A 55-year-old man without a personal or familial history of neuromuscular disease started to experience progressive muscle weakness and atrophy in the upper and lower limbs and then rapidly developed dysarthria and dysphagia. Due to respiratory failure, the patient underwent tracheostomy only 10 months after symptom onset. He
now communicates with the outside world mostly using eye movement technology. The diagnostic delay was 4 months, and the follow-up examinations did not show any cognitive impairment. Neurological examination revealed non-ambulatory tetraparesis with hyperactive deep tendon reflexes, tongue atrophy and positive Hoffman and Babinski signs. Sensory and cerebellar functions were normal. According to the El Escorial revised criteria (6), the diagnosis of definite ALS was made. Brain and spinal cord magnetic resonance imaging (MRI) were normal. Electromyography (EMG) showed some fibrillation potentials and fasciculation in the sternocleidomastoid, the first dorsal interosseous, the rectus abdominis and the tibialis anterior muscles. The results of routine blood analyses and tests for infections, cancer, autoimmune diseases, vitamin deficiencies, and toxic/metabolic diseases were all normal or negative. The findings of cerebrospinal fluid tests were unremarkable.

The affected family pedigree is shown in Figure 1. The patient's parents, brothers, and his two sons are all living and maintain good health, with no family history of neurological diseases. His mother (I-2), one of his brothers (II-3) and his two sons (III-1 and III-2) were healthy, and no positive neurological signs were identified. While his father (I-1) and his other brother (II-2) were clinically asymptomatic, physical examinations showed some positive signs. At 81 years of age, physical examination revealed that the patient's father (I-1) had grade V muscle strength; normal muscle tone; and positive palommental reflex, suck reflex and Babinski signs. The father did not undergo an EMG test. At 50 years of age, physical examination revealed that the patient's brother (II-2) had grade V muscle strength; normal muscle tone; hyperactive deep tendon reflexes; and positive suck reflex and Hoffman, Rossolimo and Babinski signs. The EMG results for brother (II-2) were normal.

First, PMP22, SOD1, TARDBP, FUS, C9orf72, KIF5A, and DCTN1 genetic screenings were performed, yielding negative results. Whole-exome sequencing (WES) was then performed on the patient. Data were analyzed aligned to the human reference genome GRCh37 using Burrows-Wheeler Aligner (BWA), Samtools and Picard, while variant calls were obtained using GATK. Variants were filtered for an allele frequency of \( < 0.01 \) according to the following online databases: the Short Genetic Variations Database (dbSNP) (https://www.ncbi.nlm.nih.gov/snp), the 1000 Genomes Project (1000G) database (http://www.1000genomes.org/), the Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org/), and gnomAD (http://gnomad.broadinstitute.org/). Sanger validation identified a heterozygous mutation, c.350dupC:p.Asp118GlyfsTer9, of FIG4 in this patient, his father (I-1) and his brother (II-2) that was not present in his other family members (Figure 2). No suspicious copy number variations (CNVs) were identified in the individuals carrying the FIG4 variant. This frameshift mutation, NM_014845: exon 4: c.350dupC: p.Asp118GlyfsTer9 (HGVS name), which has not been previously recorded in gene mutation databases, including gnomAD, ExAC, the China Metabolic Analytics Project (ChinaMAP, www.mBiobank.com), and the online Chinese Millionome Database (CMDB, https://db.cngb.org/cmdb/), was identified as a novel mutation. We predicted the impact of this variant on protein function through the use of PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), MutationTaster software (http://www.mutationtaster.org) and Combined Annotation Dependent Depletion (CADD, https://cadd.gs.washington.edu/), but no results were obtained. According to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines, the variant was interpreted as likely pathogenic of ALS (PVS1, PM2) since it
TABLE 1  Clinical phenotypes of frameshift variants and non-sense variants of the FIG4 gene identified in ALS patients.

| References       | c.DNA          | Variant       | Exon | Phenotype | Sex | Age of onset | Disease duration (yr) |
|------------------|----------------|---------------|------|-----------|-----|--------------|-----------------------|
| Chow et al. (7)  | c.67-1G>T      | p.R236*30     | 2    | FALS      | Male | 77           | 1.3                   |
| This study       | c.350dupC      | p.D118Gfs*9   | 4    | SALS      | Male | 55           | 0.83                  |
| Chow et al. (7)  | c.547C>T       | p.R183X       | 6    | SALS      | Male | 62           | 8.9                   |
| Osmanovic et al. (5) | c.759delG   | p.F254Sfs*8   | 7    | FALS      | Male | 40           | 2.67*                 |
| Lamp et al. (12) | Not available  | p.I345Yfs*17  | 9    | FALS      | Female| 65           | 3                     |
| Chow et al. (7)  | c.1207C>T      | p.Q403X       | 11   | SALS      | Female| 60           | 25                    |
| Liu et al. (10)  | c.2158G>T      | p.E720X       | 19   | SALS      | Male | 62           | 11.5                  |

* indicates that individuals are still alive.

leads to a null allele and possibly a deleterious effect (PVS1) and is not present in the control databases (gnomAD, ExAC, or dbSNP) (PM2).

**Discussion**

Heterozygous autosomal-dominant FIG4 mutations have been associated with ALS, specifically ALS1 (7). Most of the studies on FIG4 variants and ALS found that the ALS patients carrying FIG4 variants are more likely to progress slowly. Some researchers found that the European ALS patients carrying FIG4 variants were significantly upper motor neuron (UMN) predominant, and the disease duration of these patients was longer. These researchers proposed that if identified in ALS patients, FIG4 variants may serve as markers for a relatively good prognosis (5). Another Caucasian ALS patient presented with slowly progressing motor neuron disease and frontotemporal dementia (FTD), possibly associated with a heterozygous FIG4 mutation (8). Some Chinese researchers have also identified FIG4 variants in Chinese ALS patients. Zhang et al. (9) identified two FIG4 missense variants (c.658A>G p.Ile220Val and c.2063A>G p.Asp688Gly) of uncertain significance in Chinese ALS patients without a long disease duration. Recently, Chinese researchers Liu et al. (10) used targeted next-generation sequencing to identify novel FIG4 variants (c.352G>T, p.Asp118GlyfsTer9) in two Chinese ALS patients. The patient carrying the FIG4 p.Asp118GlyfsTer9 variant also presented with progressive ALS, with a Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score decreasing by 0.4 per month, although this patient still showed milder progression than our patient. One Italian ALS patient with a FIG4 variant was reported to have a disease onset at a very young age, with a rapid disease course, but the patient also had relevant cognitive impairment (11). We identified a novel c.350dupC, p.Asp118GlyfsTer9 mutation located in exon 4 of the FIG4 gene that is possibly associated with ALS. This variant thus far has not been described in patients with ALS, PLS, or CMT. Our patient with ALS presented an atypical phenotype compared with that of previously reported FIG4-variant-related cases. The most distinguishing feature was the very rapid disease course without cognitive impairment, reaching clinical endpoints only 10 months after symptom onset. Bertolin et al. (11) also reported the case of a patient with rapidly progressive ALS, a 25-year-old female carrying the FIG4 variants c.1667C>T p.T556I and c.122T>C. p.I41T together; however, our patient carried only one variant.

We summarize all frameshift variants and non-sense variants of the FIG4 gene in ALS patients that have been reported thus far in Table 1. Most of the disease durations of these patients are not long, and some of them also carry other ALS variants. We found that patients with variants that were closer to the C-terminus had longer disease courses. The FIG4 protein is composed of three domains, an interaction domain at the N-terminus, a phosphatase domain in the central region, and poly-Pro and poly-Ser domains at its C-terminus (13). In this case, the patient carried the p.Asp118GlyfsTer9 variant, which is near the N-terminal (as shown in Figure 3), is predicted to produce a shortened protein without the phosphatase domain.
and also the catalytic domain, including the active center P-loop. Therefore, the rapid progression of our patient is quite distinctive. The first two very rapidly progressing variants shown in Table 1 (p.R23fs*30 and p.D118Gfs*9) both result in the loss of expression of FIG4 protein at the mRNA level, which is important in intracellular vesicle trafficking along the endosomal-lysosomal pathway. Further biological studies investigating mutations in different domains of the FIG4 gene are still needed.

The patient’s father and brother, who were clinically asymptomatic, carried the c.350dupC mutation, and physical examinations showed some positive signs. We make two assumptions. First, we hypothesize that the variant may be incompletely penetrant for the following reasons. Some researchers have identified incomplete penetrance of a variant in a European family with ALS, which includes an unaffected father carrying a FIG4 frameshift variant, c.759delG, p.(F254Sfs*8), suggesting that FIG4 variants are not causative alone but that rare variants in multiple genes may need to be carried for individuals to show disease (5). This notion is corroborated by the finding that at least 30 genes are implicated in ALS pathogenesis, with a low percentage of ALS cases being explained by variants in each of these genes (14). Therefore, we speculate that our patient may also carry other ALS pathogenic variants with a low mutation rate that caused his ALS, which we did not detect, while his father and brother may not carry these variants. Second, the patient’s father and brother may have had PLS, which would mean that the same gene mutation in a family manifested different diseases. Continual follow-up of these two family members is needed, as well as further functional verification.

Data availability statement

The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committees of Peking University Third Hospital (Beijing, China). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

MY collected the data and wrote and submitted the manuscript for publication. XiaolL and XiaoxL diagnosed and treated the patient. YC and XiaolL revised the manuscript. DF followed the family members and reviewed and edited the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was funded by the National Natural Science Foundation of China (Grant 81873784 and 8207142).

Acknowledgments

We appreciate the participation of the patient and his family in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Oskarsson B, Gendron TE, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. (2018) 93:1617–28. doi: 10.1016/j.mayocp.2018.04.007
2. Taylor JP, Brown RH Jr, Cleveland DW. Decoding Als: from genes to mechanism. Nature. (2016) 539:197. doi: 10.1038/nature20413
3. Nicholson G, Lenk GM, Reddel SW, Grant AE, Towne CE, Ferguson CJ, et al. Distinctive genetic and clinical features of Cmt4j: a severe neuropathy caused by mutations in the P(3,5)P(2) phosphatase Fig4. Brain. (2011) 134(Pt 7):1959–71. doi: 10.1093/brain/awr148
4. Kon T, Mori F, Tanji K, Miki Y, Toyoshima Y, Yoshida M, et al. Als-associated protein Fig4 is localized in pick and lewy bodies, and also neuronal nuclear inclusions, in polyglutamine and intranuclear inclusion body diseases. 

Neuropathology. (2014) 34:19–26. doi: 10.1111/neup.12056

5. Osmanovic A, Rangnau I, Kosfeld A, Abdulla S, Janssen C, Auber B, et al. Fig4 variants in central European patients with amyotrophic lateral sclerosis: a whole-exome and targeted sequencing study. 

Eur J Hum Genet. (2017) 25:324–31. doi: 10.1038/ejhg.2016.186

6. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. 

Amyotroph Lateral Scler Other Motor Neuron Disord. (2000) 1:293–9. doi: 10.1080/146608200300079536

7. Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, et al. Deleterious variants of Fig4, a phosphoinositide phosphatase, in patients with Als. 

Am J Hum Genet. (2009) 84:85–8. doi: 10.1016/j.ajhg.2008.12.010

8. Bergner CG, Neuhofer CM, Funke C, Biskup S, von Gottberg P, Bartels C, et al. Case report: association of a variant of unknown significance in the Fig4 gene with frontotemporal dementia and slowly progressing motoneuron disease: a case report depicting common challenges in clinical and genetic diagnostics of rare neuropsychiatric and neurologic disorders. 

Front Neurol. (2020) 14:559670. doi: 10.3389/fnins.2020.559670

9. Zhang H, Cai WS, Chen SY, Liang JL, Wang ZI, Ren YT, et al. Screening for possible oligogenic pathogenesis in Chinese sporadic Als patients. 

Amyotroph Lat Scl Fr. (2018) 19:419–25. doi: 10.1080/21678421.2018.1432659

10. Liu CY, Lin JL, Feng SY, Che CH, Huang HP, Zou ZY. Novel variants in the Fig4 gene associated with chinese sporadic amyotrophic lateral sclerosis with slow progression. 

J Clin Neurol. (2022) 18:41–7. doi: 10.3988/jcn.2022.18.1.41

11. Bertolin C, Querin G, Bozzoni V, Martinelli I, De Bortoli M, Rampazzo A, et al. New Fig4 gene mutations causing aggressive Als. 

Eur J Neurol. (2018) 25:E41–2. doi: 10.1111/ene.13559

12. Lamp M, Origone P, Geroldi A, Verdianni S, Gotta F, Caponnetto C, et al. Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients. 

Neurobiol Aging. (2018) 66:179 e5–16. doi: 10.1016/j.neurobiolaging.2018.01.013

13. Baulac S, Lenk GM, Dufrennois R, Ouled Amar Bencheikh R, Cosarch P, Renard J, et al. Role of the phosphoinositide phosphatase Fig4 gene in familial epilepsy with polymicrogyria. 

Neurology. (2014) 82:1068–75. doi: 10.1212/WNL.0000000000003241

14. Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. 

Science. (2015) 347:1436–41. doi: 10.1126/science.aaa3650